Home > Search Results

Results: 5

Oral Progesterone for the Treatment of Menopausal Symptoms: A Review of the Clinical Evidence [Internet]

The purpose of this review is to examine the clinical efficacy of micronized progesterone (Prometrium), a natural, bio-identical hormone, and methoxyprogesterone acetate (MPA; Provera), a synthetic hormone, individually and comparatively, for the management of menopausal symptoms.

Rapid Response Report: Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: April 29, 2014
Show search results within this document

Drug Class Review: Hormone Therapy for Postmenopausal Women or Women in the Menopausal Transition Stage: Final Report Update # 3 [Internet]

Estrogen was approved as a hormone supplement in the 1940's to treat estrogen withdrawal symptoms in menopausal women. Estrogen production declines in women when ovarian function changes with aging or after surgical removal of the ovaries. This drop in estrogen levels can trigger a vasomotor response resulting in a sensation of flushing and sweating that interferes with function and sleep (hot flashes or flushes). Studies conducted in recent years have identified additional health benefits of postmenopausal estrogen besides symptom management (osteoporosis) as well as potential harms (cardiovascular disease, breast cancer, and cholecystitis). The purpose of this review was to compare the efficacy and adverse effects of different estrogens.

Drug Class Reviews - Oregon Health & Science University.

Version: October 2007
Show search results within this document

Menopause: Full Guideline

In summary, a large number of women in the UK experience menopausal symptoms which, in many cases, can significantly affect their quality of life. It is probable that a minority of these women seek medical treatment and for those who do there is considerable variation in the help available, with many being told that the symptoms will get better with time. Since symptoms may often continue for 7 years or more, this advice is inappropriate and help should be offered where possible. Women need to know about the available options and their risks and benefits, and be empowered to become part of the decision-making process.

NICE Guideline - National Collaborating Centre for Women's and Children's Health (UK).

Version: November 12, 2015
Show search results within this document

Urinary Incontinence in Women: The Management of Urinary Incontinence in Women

This guidance is a partial update of National Institute for Health and Care Excellence (NICE) clinical guideline 40 (published October 2006) and will replace it.

NICE Clinical Guidelines - National Collaborating Centre for Women's and Children's Health (UK).

Version: September 2013
Show search results within this document

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation

The study was unable to compare the clinical and cost-effectiveness of platinum-based therapies with non-platinum-based therapies for platinum sensitive ovarian cancer. In people with platinum-sensitive disease, paclitaxel plus platinum could be considered cost-effective compared with platinum therapies alone at a threshold of £30,000 per additional quality-adjusted life-year. In people with disease which is resistant or refractory to platinum it is unlikely that topotecan would be considered cost-effective compared with pegylated liposomal doxorubicin hydrochloride.

Health Technology Assessment - NIHR Journals Library.

Version: January 2015

Systematic Reviews in PubMed

See all (2)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...